ESMO 2022 | Combining nivolumab and ipilimumab in patients with resected stage IV melanoma

Dirk Schadendorf, MD, University Hospital Essen, Essen, Germany, describes the trial design of the Phase II IMMUNED trial (NCT02523313), a randomized, double-blind, placebo-controlled DeCOG study that investigated the efficacy of adjuvant nivolumab alone or in combination with ipilimumab versus placebo in stage IV melanoma. The primary endpoint was relapse-free survival (RFS), whereas time to progression, overall survival (OS) and safety were secondary endpoints. Patients receiving immunotherapy had superior RFS. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.